Chuck Schumer has COVID

(FiveNation.com)- Despite having “extremely modest symptoms,” Chuck Schumer tested positive for the coronavirus.

According to a statement, the Senate Majority Leader, the most senior Democrat in the Senate, has had two booster shots and is completely immunized.

Apparently, he’s not “immunized.” Anyone with a room temperature IQ can figure out by now that there is no immunization associated with shots or boosters unless you change the definition of immunity.

For the duration of the quarantine, the 71-year-old will be compelled to work from home rather than from his workplace.

According to a spokeswoman, despite the infection, he will continue with his “strong schedule” and maintain “near continual communication with his colleagues.”

Even if he is not physically present at the Capitol, the statement read, “he will continue with his busy agenda and keep in close contact with his colleagues through virtual meetings and his distinctive flip phone.”

The Senate, which is equally split between Democrats and Republicans and uses the Vice President to break ties when necessary, is scheduled to reconvene on Monday.
Schumer presented a measure last week that would allow Medicare to impact the cost of prescription medications.

The action starts a new effort to enact a reconciliation deal before the November midterm elections.

Sen. Joe Manchin of West Virginia, a centrist Democrat who failed to pass Build Back Better in December, favors the prescription medicine provision.

Other components of Build Back Better, such as those dealing with climate change and tax reform, are also being discussed by Schumer and Manchin and may win the support of West Virginians.

According to Punchbowl News, the bill is colloquially known as “Build Back Manchin.”
The website included information on the text, including the possibility that Medicare would begin negotiating prescription medication prices as early as next year if the legislation were to pass.

There would also be an “inflation rebate” to offset “arbitrary and unjustifiable price rises on items,” a ceiling on patients’ out-of-pocket expenses of $2,000 per year, the ability for patients to make monthly payments, and more.

If medicine costs rose faster than inflation, the government would require drug corporations to make the difference.

A “premium stability strategy” would be in place to restrain yearly premium rises.

The law, according to a summary of it, “changes that dynamic by rewarding manufacturers and insurers to keep medication prices down and holds them accountable for rising drug prices and spending,” according to Punchbowl.